Cancer Immunotherapy Trials Underutilize Immune Response Monitoring

Connell, C. M., Raby, S. E. M., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T. (January 2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 23 (1). pp. 116-117. ISSN 1083-7159

DOI: 10.1634/theoncologist.2017-0226


Immune-related radiological and biomarker monitoring in cancer immunotherapy trials permits interrogation of efficacy and reasons for therapeutic failure. We report the results from a cross-sectional analysis of response monitoring in 685 T-cell checkpoint-targeted cancer immunotherapy trials in solid malignancies, as registered on the U.S. National Institutes of Health trial registry by October 2016. Immune-related radiological response criteria were registered for only 25% of clinical trials. Only 38% of trials registered an exploratory immunological biomarker, and registration of immunological biomarkers has decreased over the last 15 years. We suggest that increasing the utilization of immune-related response monitoring across cancer immunotherapy trials will improve analysis of outcomes and facilitate translational efforts to extend the benefit of immunotherapy to a greater proportion of patients with cancer.

Item Type: Paper
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies > Immunotherapy
CSHL Authors:
Communities: CSHL Cancer Center Program > Signal Transduction
CSHL labs > Fearon lab
CSHL labs > Janowitz lab
CSHL Cancer Center Program > Cellular Communication in Cancer Program
Highlight: Janowitz, Tobias
Depositing User: Matt Covey
Date: January 2018
Date Deposited: 13 Oct 2017 18:27
Last Modified: 26 Oct 2020 16:02
PMCID: PMC5759814
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving